Corvus Pharmaceuticals Income Statement (2022-2025) | CRVS

Income Statement Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Operating items
Research & Development 4.59M3.97M3.96M4.08M4.11M5.22M7.45M7.87M8.45M
Selling, General & Administrative 1.98M1.65M1.59M2.18M1.82M2.03M2.47M2.39M2.12M
Restructuring Costs 0.99M0.55M0.78M0.95M0.85M0.62M
Other Operating Expenses -0.99M-0.55M-0.78M-0.95M-0.85M-0.62M
Operating Expenses 6.57M5.62M5.56M6.25M5.93M7.25M9.92M10.26M10.57M
Operating Income -6.57M-5.62M-5.56M-6.25M-5.93M-7.25M-9.92M-10.26M-10.57M
EBIT -6.57M-5.62M-5.56M-6.25M-5.93M-7.25M-9.92M-10.26M-10.57M
Non-operating items
Interest & Investment Income 0.32M0.43M0.57M0.53M0.64M0.74M
Net income details
EBT -6.14M-5.22M-5.13M-5.94M-3.69M-39.53M15.73M-7.61M-9.83M
Profit After Tax -7.87M-6.50M-6.00M-5.70M-4.26M-40.22M15.19M-8.00M-10.16M
Equity Income -1.73M-1.28M-0.86M0.24M-0.58M-0.68M-0.54M-0.39M-0.32M
Income from Continuing Operations -6.14M-5.22M-5.13M-5.94M-3.69M-39.53M15.73M-7.61M-9.83M
Consolidated Net Income -6.14M-5.22M-5.13M-5.94M-3.69M-39.53M15.73M-7.61M-9.83M
Income towards Parent Company -6.14M-5.22M-5.13M-5.94M-3.69M-39.53M15.73M-7.61M-9.83M
Net Income towards Common Stockholders -6.14M-5.22M-5.13M-5.94M-3.69M-39.53M15.73M-7.61M-9.83M
Additional items
EPS (Basic) -0.17-0.14-0.12-0.12-0.07-0.600.21-0.10-0.12
EPS (Weighted Average and Diluted) -0.17-0.14-0.12-0.12-0.07-0.60-0.13-0.10-0.12
Shares Outstanding (Weighted Average) 46.55M46.55M46.55M46.55M46.57M46.57M48.97M49.04M49.04M62.55M62.55M64.26M68.14M77.11M74.51M
Shares Outstanding (Diluted Average) 46.55M46.55M46.55M46.55M46.56M47.50M48.97M48.03M49.04M60.99M75.15M
EBITDA -7.74M-7.44M-6.08M-6.01M-4.34M-39.60M15.23M-7.89M-10.07M